Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Crossject (ALCJ)

Crossject
Date:
Sort by:
 Showing the most relevant articles for your search:EU:ALCJ
DateTimeSourceHeadlineSymbolCompany
12/02/202506:30GlobeNewswire Inc.Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive BoardEU:ALCJCrossject
19/12/202406:30GlobeNewswire Inc.Crossject confirms ZEPIZURE® supply chain readiness with another successful ISO audit for Quality Management SystemEU:ALCJCrossject
09/12/202406:30GlobeNewswire Inc.Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development AgreementEU:ALCJCrossject
22/10/202405:30GlobeNewswire Inc.Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use AuthorizationEU:ALCJCrossject
23/09/202416:00GlobeNewswire Inc.Crossject reports financial results and business highlights for the first six months of 2024EU:ALCJCrossject
22/08/202405:30GlobeNewswire Inc.Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024EU:ALCJCrossject
19/08/202415:30GlobeNewswire Inc.Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue TreatmentEU:ALCJCrossject
18/07/202405:30GlobeNewswire Inc.Crossject achieves key ZEPIZURE® manufacturing milestoneEU:ALCJCrossject
15/07/202405:30GlobeNewswire Inc.Crossject to attend H.C. Wainwright 26th Annual Global Investment ConferenceEU:ALCJCrossject
10/07/202405:30GlobeNewswire Inc.Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® EpinephrineEU:ALCJCrossject
05/07/202408:09GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
26/06/202405:30GlobeNewswire Inc.Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence studyEU:ALCJCrossject
26/06/202405:30GlobeNewswire Inc.Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence studyEU:ALCJCrossject
26/06/202405:30GlobeNewswire Inc.Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée.EU:ALCJCrossject
18/06/202410:30GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
13/06/202407:36GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
12/06/202405:30GlobeNewswire Inc.Crossject appoints Dan Chiche, MD as Chief Medical Officer North AmericaEU:ALCJCrossject
12/06/202405:30GlobeNewswire Inc.Crossject appoints Dan Chiche, MD as Chief Medical Officer North AmericaEU:ALCJCrossject
12/06/202405:30GlobeNewswire Inc.Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du NordEU:ALCJCrossject
04/06/202417:30GlobeNewswire Inc.Crossject announces highly successful closing of its €8 million rights offeringEU:ALCJCrossject
04/06/202417:30GlobeNewswire Inc.Crossject announces highly successful closing of its €8 million rights offeringEU:ALCJCrossject
04/06/202417:30GlobeNewswire Inc.Crossject annonce le vif succès de son augmentation de capital de 8 millions d’eurosEU:ALCJCrossject
30/05/202408:30GlobeNewswire Inc.Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and TherapyEU:ALCJCrossject
30/05/202408:30GlobeNewswire Inc.Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and TherapyEU:ALCJCrossject
30/05/202408:30GlobeNewswire Inc.Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and TherapyEU:ALCJCrossject
02/05/202415:30GlobeNewswire Inc.Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in EuropeEU:ALCJCrossject
02/05/202415:30GlobeNewswire Inc.Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in EuropeEU:ALCJCrossject
02/05/202415:30GlobeNewswire Inc.Crossject signe une extension géographique de l'accord de commercialisation de ZEPIZURE® en EuropeEU:ALCJCrossject
30/04/202417:05GlobeNewswire Inc.Crossject annonce le lancement d’une augmentation de capitalEU:ALCJCrossject
25/04/202405:32GlobeNewswire Inc.Crossject reports audited financial results for 2023EU:ALCJCrossject
 Showing the most relevant articles for your search:EU:ALCJ